Multiple Sclerosis and Evaluation of Vitamin D Effect

References (52)

1. 1 Vitamin D Deficiency [DOI]
2. 2 Defining the clinical course of multiple sclerosis [DOI]
3. 3 Common genetic determinants of vitamin D insufficiency: a genome-wide association study [DOI]
4. 4 Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol [DOI]
5. 5 Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis [DOI]
6. 6 Circulating 25-Hydroxyvitamin D Levels Indicative of Vitamin D Sufficiency: Implications for Establishing a New Effective Dietary Intake Recommendation for Vitamin D [DOI]
7. 7 Pathological mechanisms in progressive multiple sclerosis [DOI]
8. 8 Vitamin D2 Is as Effective as Vitamin D3 in Maintaining Circulating Concentrations of 25-Hydroxyvitamin D [DOI]
9. 9 Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis [DOI]
10. 10 Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy. [DOI]
11. 11 Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2 [DOI]
12. 12 Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice [DOI]
13. 13 Mounting Evidence for Vitamin D as an Environmental Factor Affecting Autoimmune Disease Prevalence [DOI]
14. 14 Expression of the Multiple Sclerosis-Associated MHC Class II Allele HLA-DRB1*1501 Is Regulated by Vitamin D [DOI]
15. 15 The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain [DOI]
16. 16 Modulation of inflammatory and immune responses by vitamin D [DOI]
17. 17 A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis [DOI]
18. 18 Vitamin D as an immune modulator in multiple sclerosis, a review [DOI]
19. 19 Mechanisms Underlying the Regulation of Innate and Adaptive Immunity by Vitamin D [DOI]
20. 20 Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis [DOI]
21. 21 CSF cytokines/chemokines as biomarkers in neuroinflammatory CNS disorders: A systematic review [DOI]
22. 22 Safety of vitamin D3 in adults with multiple sclerosis [DOI]
23. 23 Multiple sclerosis: Decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D [DOI]
24. 24 UV radiation suppresses experimental autoimmune encephalomyelitis independent of vitamin D production [DOI]
25. 25 Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis [DOI]
26. 26 Vitamin D and seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis [DOI]
27. 27 A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis [DOI]
28. 28 Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b [DOI]
29. 29 Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis [DOI]
30. 30 Altered intestinal permeability in patients with relapsing–remitting multiple sclerosis: A pilot study [DOI]
31. 31 Fatigue Management in Multiple Sclerosis [DOI]
32. 32 Vitamin D3 alters microglia immune activation by an IL-10 dependent SOCS3 mechanism [DOI]
33. 33 The Multiple Sclerosis (MS) Genetic Risk Factors Indicate both Acquired and Innate Immune Cell Subsets Contribute to MS Pathogenesis and Identify Novel Therapeutic Opportunities [DOI]
34. 34 Cerebellar Dysfunction in Multiple Sclerosis [DOI]
35. 35 1,25‐dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking [DOI]
36. 36 VARIATION IN THE VITAMIN D RECEPTOR GENE IS ASSOCIATED WITH MULTIPLE SCLEROSIS IN AN AUSTRALIAN POPULATION [DOI]
37. 37 Sexual function in multiple sclerosis and associations with demographic, disease and lifestyle characteristics: an international cross-sectional study [DOI]
38. 38 25-Hydroxyvitamin D in cerebrospinal fluid during relapse and remission of multiple sclerosis [DOI]
39. 39 Afferent visual pathways in multiple sclerosis: a review [DOI]
40. 40 Vitamin D 3 supplementation in multiple sclerosis: Symptoms and biomarkers of depression [DOI]
41. 41 Multimodal evoked potentials for functional quantification and prognosis in multiple sclerosis [DOI]
42. 42 Seasonal variations of 25-OH vitamin D serum levels are associated with clinical disease activity in multiple sclerosis patients [DOI]
43. 43 Effects of cognitive impairment on prosodic parameters of speech production planning in multiple sclerosis [DOI]
44. 44 Vitamin D treatment in multiple sclerosis [DOI]
45. 45 Are commonly recommended dosages for vitamin D supplementation too low? Vitamin D status and effects of supplementation on serum 25-hydroxyvitamin D levels—an observational study during clinical practice conditions [DOI]
46. 46 Hypovitaminosis D upscales B-cell immunoreactivity in multiple sclerosis [DOI]
47. 47 Low Serum Vitamin D Levels and Recurrent Inflammatory Spinal Cord Disease [DOI]
48. 48 Vitamin D and phenotypes of bronchial asthma [DOI]
49. 49 The expression of VDR mRNA but not NF-κB surprisingly decreased after vitamin D treatment in multiple sclerosis patients [DOI]
50. 50 Effect of vitamin D replacement on immunological biomarkers in patients with multiple sclerosis [DOI]
51. 51 Multiple Sclerosis: Mechanisms and Immunotherapy [DOI]
52. 52 Genomic Effects of the Vitamin D Receptor: Potentially the Link between Vitamin D, Immune Cells, and Multiple Sclerosis [DOI]

Cited by 0

No indexed citations yet.

Related research

• An Overview on the Aetiology and Treatment of Alzheimer's Disease — shares topic coverage
• Proposal and Point of View on Targeting α-synuclein for the Treatment of Parkinson's Disease — shares topic coverage
• Autophagy: A Critical Review of Cellular Homeostasis and Pathophysiology — shares topic coverage
• Natural Medicines Enhancing Neurite Growth in Central Nervous System Disorders: A Review — shares topic coverage
• Neuroprotective Properties of NMDA R1 Antagonist (Ketamine) in Cyanide Treated Neurons in vitro — shares topic coverage